CDK4 and malignant colon neoplasm: In a murine colon cancer model, CDK4 knockout along with antibodies against programmed death-ligand 1 (PD-L1) enhanced antitumour immune responses, whereas in melanoma model mice, CDK4/6 inhibition reversed the resistance to ICIs [158–160].